Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Jun 9;6(6):e011276.
doi: 10.1136/bmjopen-2016-011276.

SWIM (sickle with ibuprofen and morphine) randomised controlled trial fails to recruit: lessons learnt

Gavin Cho  1 , Kofi A Anie  2 , Jacky Buckton  1 , Patricia Kiilu  1 , Mark Layton  3 , Lydia Alexander  4 , Claire Hemmaway  5 , Dorothy Sutton  5 , Claire Amos  6 , Caroline J Doré  6 , Brennan Kahan  6 , Sarah Meredith  6
Affiliations
Randomized Controlled Trial

SWIM (sickle with ibuprofen and morphine) randomised controlled trial fails to recruit: lessons learnt

Gavin Cho et al. BMJ Open. .

Abstract

Objectives: Sickle With Ibuprofen and Morphine (SWIM) trial was designed to assess whether co-administration of ibuprofen (a non-steroidal anti-inflammatory drug) resulted in a reduction of opioid consumption delivered by patient-controlled analgesia (PCA) for acute pain in sickle cell disease.

Design: A randomised, placebo-controlled, double-blind trial.

Setting: UK multicentre trial in acute hospital setting.

Participants: Adults with sickle cell disease of any gender and phenotype aged 16 years and over.

Interventions: Oral ibuprofen at a dose of 800 mg three times daily or placebo in addition to opioids (morphine or diamorphine) administered via PCA pump for up to 4 days.

Main outcome measures: The primary outcome measure was opioid consumption over 4 days following randomisation.

Results: The SWIM trial closed early because it failed to randomise to its target of 316 patients within a reasonable time.

Conclusions: The key issues identified include the unanticipated length of time between informed consent and randomisation, difficulties in randomisation of patients in busy emergency departments, availability of trained staff at weekends and out of hours, fewer centres than expected using PCA routinely for sickle cell pain treatment, lack of research staff and support for participation, and the trial design. There are implications for future UK trials in sickle cell disease.

Trial registration number: ISRCTN97241637, NCT00880373; Pre-results.

Keywords: ACCIDENT & EMERGENCY MEDICINE; IBUPROFEN; OPIOIDS; PAIN MANAGEMENT; SICKLE CELL DISEASE.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of patient recruitment at SWIM trial closure.
See this image and copyright information in PMC

References

    1. Aljuburi G, Laverty AA, Green SA et al. Trends in hospital admissions for sickle cell disease in England, 2001/02-2009/10. J Public Health (Oxf) 2012;34:570–6. 10.1093/pubmed/fds035 - DOI - PubMed
    1. Gillis VL, Senthinathan A, Dzingina M et al. Guideline Development Group. Management of an acute painful sickle cell episode in hospital: summary of NICE guidance. BMJ 2012;344:e4063 10.1136/bmj.e4063 - DOI - PubMed
    1. Dunlop RJ, Bennett KC. Pain management for sickle cell disease. Cochrane Database Syst Rev 2006;(2):CD003350 10.1002/14651858.CD003350.pub2 - DOI - PubMed
    1. Bartolucci P, El Murr T, Roudot-Thoravel F et al. A randomized, controlled clinical trial of ketoprofen for sickle cell disease vaso-occlusive crises in adults. Blood 2009;114:3742 10.1182/blood-2009-06-227330 - DOI - PubMed
    1. Collins SL, Moore RA, McQuay HJ et al. Single dose oral ibuprofen and diclofenac for postoperative pain. Cochrane Database Syst Rev 2008;3:CD001548. - PubMed

Publication types

Associated data